Delgocitinib for treating moderate to severe chronic hand eczema after 1 previous therapy

Delgocitinib is currently in clinical development for the treatment of adults with moderate to severe chronic hand eczema. Hand eczema is one of the most common types of eczema. It mainly affects the palms but can also affect other parts of the hand. Chronic hand eczema is hand eczema that lasts for more than three months or relapses twice or more within a year. It is characterised by dry, itchy, and painful skin that is red or darker than the surrounding skin. In severe cases, the hands can become very painful, making it difficult to carry out day-to-day tasks. Chronic hand eczema is a significant disease burden and traditionally has had limited treatment options beyond topical and short-term systemic medicines.